Valeant Pharmaceuticals Intl Inc has many well-known and vocal supporters in the hedge fund industry. Bill Ackman is perhaps the most notable of these advocates, due to the hedge fund billionaire’s oversized position in the former market darling.
Jeffrey Ubben’s ValueAct Capital also owns a significant stake in the drug maker. According to the fund’s most recent 13F filing, ValueAct owned just under 15 million shares of Valeant at the end of the fourth quarter, around 10.6% of the hedge fund’s equity portfolio at the time making it the fund’s second-largest holding after Microsoft (21.8% of the fund’s equity portfolio).
ValueAct Falls 2.2% In 2015; Still Likes Valeant
And even after Valeant Pharmaceuticals Intl's recent troubles, ValueAct believes that the company...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
